DE69426690D1 - Behandlung von atrophischer Haut und Vagina - Google Patents

Behandlung von atrophischer Haut und Vagina

Info

Publication number
DE69426690D1
DE69426690D1 DE69426690T DE69426690T DE69426690D1 DE 69426690 D1 DE69426690 D1 DE 69426690D1 DE 69426690 T DE69426690 T DE 69426690T DE 69426690 T DE69426690 T DE 69426690T DE 69426690 D1 DE69426690 D1 DE 69426690D1
Authority
DE
Germany
Prior art keywords
vagina
treatment
atrophic skin
atrophic
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69426690T
Other languages
English (en)
Other versions
DE69426690T2 (de
Inventor
George Joseph Cullinan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of DE69426690D1 publication Critical patent/DE69426690D1/de
Application granted granted Critical
Publication of DE69426690T2 publication Critical patent/DE69426690T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
DE69426690T 1993-12-21 1994-12-19 Behandlung von atrophischer Haut und Vagina Expired - Fee Related DE69426690T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/171,087 US5461064A (en) 1993-12-21 1993-12-21 Methods of inhibiting atrophy of the skin and vagina

Publications (2)

Publication Number Publication Date
DE69426690D1 true DE69426690D1 (de) 2001-03-22
DE69426690T2 DE69426690T2 (de) 2001-08-09

Family

ID=22622468

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69426690T Expired - Fee Related DE69426690T2 (de) 1993-12-21 1994-12-19 Behandlung von atrophischer Haut und Vagina

Country Status (17)

Country Link
US (2) US5461064A (de)
EP (1) EP0664124B1 (de)
JP (1) JPH07215860A (de)
KR (1) KR950016732A (de)
CN (1) CN1108097A (de)
AU (1) AU699948B2 (de)
CA (1) CA2138511A1 (de)
CZ (1) CZ321594A3 (de)
DE (1) DE69426690T2 (de)
ES (1) ES2153851T3 (de)
HU (1) HUT71221A (de)
IL (1) IL112041A0 (de)
NO (1) NO944919L (de)
NZ (1) NZ270173A (de)
PH (1) PH31600A (de)
RU (1) RU2143897C1 (de)
ZA (1) ZA9410078B (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
ATE406909T1 (de) 1993-05-13 2008-09-15 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US5811120A (en) * 1994-03-02 1998-09-22 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
US5972383A (en) * 1994-03-02 1999-10-26 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
CA2234060A1 (en) * 1995-10-06 1997-04-10 Arch Development Corporation Methods and compositions for viral enhancement of cell killing
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
US5827876A (en) * 1996-04-09 1998-10-27 American Home Products Corporation Inhibition of bone loss by 3-(4-acrylamidobenzoyl) benzo b!-thiophenes
AU6959898A (en) * 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
US6488940B2 (en) * 1997-08-21 2002-12-03 Johnson & Johnson Consumer Companies, Inc. Use of 17-α-estradiol for the treatment of aged or sundamaged skin and/or skin atrophy
US20040044080A1 (en) * 1997-10-28 2004-03-04 Place Virgil A. Treatment of dyspareunia with topically administered nitroglycerin formulations
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
JP5005127B2 (ja) 1999-05-04 2012-08-22 ストラカン・インターナショナル・リミテッド アンドロゲングリコシド及びそのアンドロゲン作用活性
US6245819B1 (en) * 2000-07-21 2001-06-12 Hormos Medical Oy, Ltd. Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause
IL145838A (en) * 2000-10-16 2008-11-03 Pfizer Prod Inc Use of an estrogen agonist / antagonist to produce a drug for the treatment of vaginitis
US7906480B2 (en) * 2002-05-23 2011-03-15 Michael Holick Use of a parathyroid hormone peptide analogs for the treatment of vaginal atrophy
DE60309465T2 (de) * 2002-06-06 2007-08-30 Hormos Medical Ltd. Verfahren zur Hemmung oder Vorbeugung von urogenitaler Atrophie und deren Symptome bei Frauen
CA2654152A1 (en) 2006-06-02 2007-12-13 Pear Tree Women's Health Care Method of treating atrophic vaginitis
US8097660B2 (en) * 2006-08-31 2012-01-17 Bayer Materialscience Llc Rigid polyurethane foams with low thermal conductivity and a process for their production
US20080139513A1 (en) * 2006-09-26 2008-06-12 Novavax, Inc. Transdermal deliver of active agents
CN101636372B (zh) 2007-02-14 2013-03-27 霍尔莫斯医疗有限公司 有治疗价值的三苯基丁烯衍生物的制备方法
WO2008099060A2 (en) 2007-02-14 2008-08-21 Hormos Medical Ltd Methods for the preparation of fispemifene from ospemifene
JP6174156B2 (ja) 2012-10-19 2017-08-02 フェルミオン オサケ ユキチュア オスペミフェンの製造方法
EP3854382B1 (de) 2015-06-01 2023-10-04 Durga Enterprises, LLC Zusammensetzungen zur behandlung von atrophischer vaginitis, peri- und postmenopausaler dyspareunie und/oder oophorektomierten frauen und behandlungsverfahren damit
ES2843052T3 (es) * 2017-12-14 2021-07-15 Bitop Ag Ectoína y derivados de ectoína para su uso en afecciones vulvovaginales

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
WO1993010742A2 (en) * 1991-11-27 1993-06-10 Novo Nordisk A/S Chemical compounds, their preparation and use

Also Published As

Publication number Publication date
US5461064A (en) 1995-10-24
IL112041A0 (en) 1995-03-15
ES2153851T3 (es) 2001-03-16
NZ270173A (en) 1996-08-27
PH31600A (en) 1998-11-03
HUT71221A (en) 1995-11-28
RU94044436A (ru) 1996-10-20
US5610167A (en) 1997-03-11
ZA9410078B (en) 1996-06-19
CA2138511A1 (en) 1995-06-22
KR950016732A (ko) 1995-07-20
NO944919L (no) 1995-06-22
JPH07215860A (ja) 1995-08-15
EP0664124A1 (de) 1995-07-26
RU2143897C1 (ru) 2000-01-10
EP0664124B1 (de) 2001-02-14
CN1108097A (zh) 1995-09-13
NO944919D0 (no) 1994-12-19
AU8154294A (en) 1995-06-29
HU9403655D0 (en) 1995-02-28
AU699948B2 (en) 1998-12-17
DE69426690T2 (de) 2001-08-09
CZ321594A3 (en) 1995-09-13

Similar Documents

Publication Publication Date Title
DE69426690T2 (de) Behandlung von atrophischer Haut und Vagina
DE68928051D1 (de) Behandlung von humanem Kollagen und Verwendung als Auto-Implantat
DE3855489T2 (de) Behandlung von Hautfalten
ATE433760T1 (de) Vorbeugung und behandlung von amyloidogener krankheit
DE69302257T2 (de) Pilzhemmendes und hautheilungsförderndes Mittel
DE69530597D1 (de) Behandlung von Obst und Gemüse
DE68916036T2 (de) Mittel zur behandlung und prophylaxe koronarer und zerebraler ischämischer erkrankungen.
DE229654T1 (de) Behandlung von nicht-akne-entzuendlichen und -infektioesen hautkrankheiten und haarausfall.
ATA11989A (de) Mittel zur vorbeugung gegen und behandlung von parodontopathien
DE69729817D1 (de) Behandlung von Aldehyd-fixierten Geweben
DK295190D0 (da) Kosmetik- og hudbehandlingssammensaetninger
DE69841550D1 (de) Behandlung von fibromyalgie und verwandten erkrankungen
DE69306335D1 (de) Prevention und Behandlung von Atherosclerosis
DE69132054D1 (de) Behandlung von windelausschlag
DE69120933D1 (de) Topische Anwendung von Glycosaminoglykane zur Prävention und Behandlung der Zervikal- oder Vaginalerkrankungen
DE69520268T2 (de) Behandlung von Legierungen und danach hergestellte Gegenstände
DE69308762D1 (de) Behandlung des Muskulschwunds
DE59306085D1 (de) Haar- und körperbehandlungsmittel
DE69429259D1 (de) Behandlung von futtern und fasergut
AT400224B (de) Mittel zur behandlung und pflege von hufen
ATE274328T1 (de) Behandlung und fixierung von gewebe
DE3881377T2 (de) Mittel zur prophylaxe und behandlung von thrombocytopenie.
DE29507158U1 (de) Mittel zur Behandlung und Pflege von Haaren und Kopfhaut
NO934599D0 (no) Fremgangsmaate og anordning for reduksjon av hudvev
DE59408477D1 (de) Therapieeinrichtung zur behandlung von leiden des herzens und herznaher gefässe

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee